Open AccessAdverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes
Author(s) -
Halis Kaan Aktürk,
Aaron Michels
Publication year - 2020
Publication title -
current opinion in endocrinology, diabetes and obesity./current opinion in endocrinology, diabetes and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.199
H-Index - 67
eISSN - 1752-2978
pISSN - 1752-296X
DOI - 10.1097/med.0000000000000546
Subject(s) - medicine , diabetic ketoacidosis , type 1 diabetes , adverse effect , diabetes mellitus , type 2 diabetes , immune system , immunology , ipilimumab , immunotherapy , ketoacidosis , cancer , intensive care medicine , endocrinology
To summarize a new form of autoimmune diabetes as an adverse event of specific cancer immunotherapies. Immune checkpoint inhibitors are revolutionary treatments in advanced cancers; however, they can cause type 1 diabetes following treatment with these state-of-the-art therapies.